SCHEMBL7616209

SCHEMBL7616209

CC(=O)N[C@H]1[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O[C@H]1CCN

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ POLB P06746 2/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ CA1 P00915 8/20 0.49
▸ CA2 P00918 8/20 0.49
▸ CA9 Q16790 8/20 0.49
▸ CA12 O43570 7/20 0.49
▸ CYP3A4 P08684 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ THRB P10828 2/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ MMP12 P39900 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ TSHR P16473 1/20 0.44
▸ NR3C1 P04150 1/20 0.44
▸ FYN P06241 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16392999 0.91 LMNA (0.56) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL18349642 0.90 LMNA (0.49) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL30980616 0.88 LMNA (0.54) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL16393027 0.88 LMNA (0.54) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL16393065 0.88 LMNA (0.54) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL28694159 0.85 LMNA (0.53) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL31538817 0.84 LMNA (0.56) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL22899114 0.84 LMNA (0.50) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL18349732 0.84 LMNA (0.50) LMNAKMT2APOLBALDH1A1CA1
SCHEMBL17417919 0.83 LMNA (0.52) LMNAKMT2APOLBALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020107224-A1 Non-mucin type synthetic compounds or its carrier conjugated compounds KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107224-A1 Non-mucin type synthetic compounds or its carrier conjugated compounds MUC1, FUT5, ST6GAL1 LMNA 4472/4885KMT2A 2303/4885POLB 1709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback